key: cord-0682350-d809wj4m
authors: Fogarty, Helen; Karampini, Ellie; O'Donnell, Andrew S.; Ward, Soracha E.; O'Sullivan, Jamie M.; O'Donnell, James S.
title: Persistent endotheliopathy in the pathogenesis of long COVID syndrome ‐ Reply to comment from von Meijenfeldt et al.
date: 2021-11-22
journal: J Thromb Haemost
DOI: 10.1111/jth.15578
sha: eaf1ca623550d66f16cab83f5a22abfe0c6e5410
doc_id: 682350
cord_uid: d809wj4m

We are grateful for the comments and the interesting additional novel data presented by von Meijenfeldt et al [1]. These findings provide further evidence that sustained endotheliopathy and coagulopathy are both common in patients following acute COVID-19 [2-5]. The longitudinal data presented provide additional insights into the duration of specific aspects of COVID-19-induced hemostatic dysfunction. Previous studies have reported elevated D-dimer levels in 25% of patients in the first few months post-SARS-CoV-2 infection [2, 5]. Notwithstanding differences in patient cohorts and study design, von Meijenfeldt et al show that these elevated D-dimer levels after acute COVID appear to normalize by 4 months [1]. Given that convalescent COVID-19 patients commonly present with respiratory symptoms, this observation has important clinical implications with respect to the utility of D-dimer testing in pulmonary embolism testing algorithms.

We are grateful for the comments and the interesting additional novel data presented by von Meijenfeldt et al. 1 These findings provide further evidence that sustained endotheliopathy and coagulopathy are both common in patients following acute COVID-19. [2] [3] [4] [5] The longitudinal data presented provide additional insights into the duration of specific aspects of COVID-19-induced hemostatic dysfunction. Previous studies have reported elevated D-dimer levels in 25% of patients in the first few months after SARS-CoV-2 infection. 2, 5 Notwithstanding differences in patient cohorts and study design, The key question posed by our collective data is whether persistent hemostatic dysfunction following COVID-19 is contributing to post-acute sequelae of SARS-CoV-2 infection (PASC or long COVID syndrome). 9 In our study, we observed weak associations between 6-min walk test distance and both VWF:Ag and VWF propeptide levels at a median of 68 days after acute COVID-19. 4 In contrast, using the subjective Sheehan disability scale to assess functional impairment, von Meijenfeldt et al. found no relationship with any hemostatic biomarkers at either 8 or 12 months after discharge. 1 The differences in these results may be attributable to a variety of potential confounders. In particular, both studies included a relatively small number of patients (n = 50 and n = 44, respectively), and long COVID symptomatology was assessed using a combination of objective and subjective protocols performed at varying time points following discharge. Moreover, there were also differences between the study cohorts with respect to initial COVID-19 severity; patient comorbidities including obesity; and differences in patient management during acute COVID-19 (including anticoagulant therapy intensity). Finally, accumulating recent data have highlighted signif-

Persistent endotheliopathy in the pathogenesis of long COVID syndrome. Comment from von Meijenfeldt et al

Prolonged elevation of Ddimer levels in convalescent COVID-19 patients is independent of the acute phase response

Sustained prothrombotic changes in COVID-19 patients 4 months after hospital discharge

Persistent endotheliopathy in the pathogenesis of long COVID syndrome

Hemostasis and fibrinolysis in COVID-19 survivors 6 months after intensive care unit discharge

The ADAMTS13-von Willebrand factor axis in COVID-19 patients

ADAMTS13 regulation of VWF multimer distribution in severe COVID-19

Von Willebrand factor propeptide in severe coronavirus disease 2019 (COVID-19): evidence of acute and sustained endothelial cell activation

Long COVID or post-acute sequelae of COVID-19 (PASC): an overview of biological factors that may contribute to persistent symptoms

Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19